Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R 1 -R 14 are as described herein. Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with the compound described herein and also contacting the cancer cells with an apoptosis inducing ligand, whereby apoptosis is induced in the cancer cells.
1. A method of synergistically enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand or of inducing apoptosis in cancer cells in a mammal that are resistant to treatment with an apoptosis inducing ligand comprising administering to the mammal a therapeutically effective amount of a compound of the formula:
wherein R 1 is H and R 2 is selected from C 1 -C 6 acyloxy, heteroarylcarbonyloxy, a group of the formula:
or, R 1 and R 2 taken together, form ═O,
X is NH or is absent,
m and o are integers of from 1 to about 10,
n is 0 or 1,
R 3 and R 4 are independently OH or C 1 -C 6 alkoxy or, taken together, form a double bond or an epoxy ring,
R 5 is H or C 1 -C 6 acyloxy,
R 6 is H, OH, or C 1 -C 6 acyloxy,
R 7 and R 9 are independently CH 3 or CH 2 OH,
R 8 and R 10 , taken together with the carbon atoms to which they are attached, form a double bond, and
R 11 and R 12 are both H, R 11 is H and R 12 is —OSO 3 H, R 11 is H and R 12 is imidazolyl, or R 11 and R 12 taken together with the carbon atoms to which they are attached, form a double bond, and
administering an effective amount of an apoptosis-inducing ligand, whereby a synergistic enhancement of the response is obtained or whereby apoptosis is induced in the cancer cells.
2. The method according to claim 1 , wherein R 11 and R 12 , taken together, form a double bond, R 3 and R 4 , taken together, form an epoxy ring, R 5 is H, R 7 and R 9 are CH 3 , and R 8 and R 19 , taken together, form a double bond.
3. The method according to claim 2 , wherein R 1 is H and R 2 is C 1 -C 6 acyloxy.
4. The method according to claim 3 , wherein the compound is of the formula:
5. The method according to claim 2 , wherein the compound is of the formula:
6. The method according to claim 2 , wherein R 1 is H and R 2 is a group of the formula:
wherein m and o are integers of from 1 to about 10, and
n is 0 or 1.
7. The method according to claim 6 , wherein the compound is of the formula:
8. The method according to claim 1 , wherein the compound is of the formula:
9. The method according to claim 1 , wherein the cancer cells express a TNF receptor or a toll-like receptor.
10. The method according to claim 1 , wherein the apoptosis-inducing ligand is selected from TRAIL, TNF-α, FasL, an anti-DR4 antibody, an anti-DR5 antibody, and poly IC.
11. The method according to claim 1 , further comprising administering to the mammal an Smac mimetic which is birinapant, GDC-015, or LCL-161, a Bcl-2 antagonist which is ABT-199, ABT-737, or venetoclax, or a combination thereof.
12. The method according to claim 1 , wherein the cancer cells are associated with a cancer selected from glioma, thyroid carcinoma, breast carcinoma, small-cell lung carcinoma, non-small-cell lung carcinoma, gastric carcinoma, colon carcinoma, gastrointestinal stromal carcinoma, pancreatic carcinoma, bile duct carcinoma, CNS carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, renal carcinoma, skin carcinoma, melanoma, basal cell carcinoma, squamous cell carcinoma, anaplastic large-cell lymphoma, multiple myeloma, leukemia, lymphoma, cervical carcinoma, and mesothelioma, follicular thyroid carcinoma, colorectal cancer, myeloid leukemia, hepatic cancer, hepatocellular carcinoma, cholangiocarcinoma, cervical and ovarian cancer, cancers of glial origin, and combinations thereof.
13. The method according to claim 1 , wherein the compound is of the formula:
14. A compound of the formula:
wherein R 1 is H and R 2 is a group of the formula:
X is NH or is absent,
m and o are integers of from 1 to about 10,
n is 0 or 1,
R 3 and R 4 , taken together, form an epoxy ring,
R 5 is H,
R 6 is H, OH, or C 1 -C 6 acyloxy,
R 7 and R 9 are CH 3 ,
R 8 and R 19 , taken together with the carbon atoms to which they are attached, form a double bond, and
R 11 and R 12 taken together with the carbon atoms to which they are attached, form a double bond.
15. The compound of claim 14 , wherein the compound is of the formula:
16. A method of synergistically enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand or of inducing apoptosis in cancer cells in a mammal that are resistant to treatment with an apoptosis inducing ligand comprising administering to the mammal a therapeutically effective amount of a compound of the formula:
and administering an effective amount of an apoptosis-inducing ligand, whereby a synergistic enhancement of the response is obtained or whereby apoptosis is induced in the cancer cells, and wherein the apoptosis-inducing ligand is TNF-α, FasL, or poly IC.
17. The method of claim 16 , wherein the cancer cells are associated with a cancer selected from glioma, thyroid carcinoma, breast carcinoma, small-cell lung carcinoma, non-small-cell lung carcinoma, gastric carcinoma, colon carcinoma, gastrointestinal stromal carcinoma, pancreatic carcinoma, bile duct carcinoma, CNS carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, renal carcinoma, skin carcinoma, melanoma, basal cell carcinoma, squamous cell carcinoma, anaplastic large-cell lymphoma, multiple myeloma, leukemia, lymphoma, cervical carcinoma, and mesothelioma, follicular thyroid carcinoma, colorectal cancer, myeloid leukemia, hepatic cancer, hepatocellular carcinoma, cholangiocarcinoma, cervical and ovarian cancer, cancers of glial origin, and combinations thereof.
18. The method according to claim 16 , further comprising administering to the mammal an Smac mimetic which is birinapant, GDC-015, or LCL-161, a Bcl-2 antagonist which is ABT-199, ABT-737, or venetoclax, or a combination thereof.